Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

15.45
Delayed Data
As of Dec 02
 +0.14 / +0.91%
Today’s Change
13.77
Today|||52-Week Range
119.87
-84.80%
Year-to-Date
Is Mylan Being Really Smart -- Or Really Arrogant?
6:54am / MotleyFool.com - Paid Partner Content
Valeant, Salix, Sales Force and Asset Sales
Nov 30 / GuruFocus News - Paid Partner Content
3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017
Dec 01 / MotleyFool.com - Paid Partner Content
How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, Mor...
Nov 30 / TheStreet.com - Paid Partner Content
Frontrunning: December 1
Dec 01 / Investing Channel - Paid Partner Content
Valeant and Tribune Media Rebounds Not in Sight
Nov 30 / TheStreet.com - Paid Partner Content
SEC Discloses Correspondence Over Valeant's Accounting Practices
Nov 30 / TheStreet.com - Paid Partner Content
Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls
Nov 30 / TheStreet.com - Paid Partner Content
Why Valeant Pharmaceuticals, Costamare, and First Bancorp Slumped Today
Nov 30 / MotleyFool.com - Paid Partner Content
Valeant Plummets on Reports of Salix Takeover Breakdown
Nov 30 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close15.31
Today’s open15.48
Day’s range15.18 - 15.75
Volume8,596,498
Average volume (3 months)22,126,141
Market cap$5.3B
Dividend yield--
Data as of 4:00pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-46.13%
Earnings growth (next 5 years)+9.80%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book0.90

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...+1.67+4.04%
UTHRUnited Therapeutics ...-0.47-0.37%
MNKMallinckrodt Plc+0.51+0.96%
OPKOPKO Health Inc+0.09+0.87%
Data as of 4:02pm ET, 12/02/2016

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)$1.25
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts


Search for Jobs